A 48-year-old female with major depressive disorder and comorbid fibromyalgia was started on duloxetine 60 mg daily ten weeks ago. Her baseline PHQ-9 was 21 and her Brief Pain Inventory (BPI) average pain severity score was 7.2 out of 10. At today's visit, her PHQ-9 is 12 and her BPI average pain severity score is 5.8. She reports improved mood, motivation, and energy, but continues to endorse significant widespread musculoskeletal pain, fatigue, and nonrestorative sleep. She rates the overall change in her condition as minimally improved. Her blood pressure is 128/82 mmHg, up from a baseline of 118/76 mmHg. She denies nausea, headaches, or urinary hesitancy. The PMHNP is evaluating the dual efficacy of duloxetine for both conditions. Which of the following best represents the appropriate evaluation?